The market for solid state services (including salt, polymorph and crystallization screening) is around $150M and there is a growing trend from pharmaceutical companies to outsource much of this activity to CDMOs such as Cambrex. 

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. It will present two Cambrex case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

Register Now